Zhi Tong Cai Jing·2026-03-30 15:05Core Viewpoint - The company reported a revenue of approximately 6.67 billion RMB for the year ending December 31, 2025, reflecting a year-on-year growth of 14.91% [1] - The net profit attributable to shareholders was around 1.13 billion RMB, an increase of 19.35% compared to the previous year [1] - The company plans to distribute a dividend of 13.00 RMB per 10 ordinary shares (including tax) [1] Revenue Breakdown - Revenue from large pharmaceutical companies amounted to 2.92 billion RMB, showing a year-on-year growth of 8.36% [1] - Revenue from small and medium-sized pharmaceutical companies reached 3.76 billion RMB, with a significant year-on-year increase of 20.57% [1] - The revenue sources are becoming increasingly diversified, indicating a broader market strategy [1]